An Open Label Extension Study Evaluating the Safety of Long Term Dosing of AMG 531 in Thrombocytopenic Subjects with Myelodysplastic Syndromes (MDS)

Trial Profile

An Open Label Extension Study Evaluating the Safety of Long Term Dosing of AMG 531 in Thrombocytopenic Subjects with Myelodysplastic Syndromes (MDS)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Apr 2016

At a glance

  • Drugs Romiplostim (Primary)
  • Indications Myelodysplastic syndromes
  • Focus Adverse reactions
  • Sponsors Amgen
  • Most Recent Events

    • 14 Apr 2016 This trial was completed in Spain,Hungary, Austria, Slovakia, Poland (end date: 2011-06-28), Czech Republic (end date: 2011-09-28), Denmark, Germany (end date: 2011-02-23), Belgium (end date: 2011-07-18), and in Netherlands according to European Clinical Trials Database record.
    • 21 Apr 2012 Planned end date changed from 23 Feb 2011 to 23 Feb 2012 as reported by European Clinical Trials Database record.
    • 24 Mar 2012 Planned end date changed from 5 Jun 2011 to 23 Feb 2011 as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top